secwatch.observer — SEC 8-K summary
======================================

Issuer:     Chemomab Therapeutics Ltd. (CMMB)
CIK:        0001534248
Form:       8-K
Filed at:   2022-06-01T23:59:59+00:00
Accession:  0001178913-22-002261
Event type: leadership
Sentiment:  neutral
Materiality: 0.20
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Chemomab Director Joel Maryles to step down at 2022 AGM
-------------------------------------------------------

- Joel Maryles, Class I director, notified Chemomab on May 31, 2022 he will not seek re-election.
- Departure effective at the 2022 Annual General Meeting on June 7, 2022.
- Departure not due to any disagreement with the Company, management, board, or operations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534248/000117891322002261/0001178913-22-002261-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534248/000117891322002261/form8k.htm
  HTML page:      https://secwatch.observer/filing/0001178913-22-002261

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer